NOT FDA-APPROVED

GHK-Cu

A small copper-binding peptide with a 50-year track record in skin research. The most-studied peptide for skin tone, collagen, and aesthetics, and the one cosmetic chemists have been quietly using for decades.

The 30-second read

GHK-Cu is a tiny three-amino-acid peptide that naturally binds copper. It was discovered in human plasma in the 1970s by dermatology researcher Loren Pickart, and it's been in cosmetic chemistry literature ever since. Topically, the evidence for skin firmness, collagen synthesis, and reducing fine lines is the strongest of any peptide, though "strongest" still means small studies and modest effect sizes. As a research peptide for injection, the data is much thinner. The peptide isn't FDA-approved as a drug, but it shows up in plenty of FDA-permitted cosmetic products, where the regulatory bar is much lower than for drugs. The science is real; the marketing is louder than the science.

Why this peptide is on people's radar

Of the peptides being studied for skin and aesthetics, GHK-Cu has by far the longest research history. Loren Pickart first identified the GHK sequence in human plasma in 1973, while studying why blood from younger donors produced different effects in tissue cultures than blood from older donors. The copper-binding form (GHK-Cu) emerged as the more biologically active version, and it has been studied continuously in dermatology and wound-healing research ever since.

In the consumer skincare world, that long history shows up as ingredient labels: copper-peptide serums, lift-and-firm creams, post-procedure recovery products. Research-peptide communities pulled GHK-Cu out of cosmetic chemistry and into broader peptide stacks like "GLOW" (BPC-157 + TB-500 + GHK-Cu) and "KLOW" (the same with KPV added), though those combinations have no published human studies behind them.

Three things keep the conversation alive: the topical data is genuinely better than for most "anti-aging" actives; the gene-expression studies (which suggest GHK-Cu nudges hundreds of human genes back toward a younger pattern) are striking and get repeated everywhere; and copper-peptide skincare is one of the few peptide categories where products are widely available without a prescription and used without injections.

What people are usually trying to do with it

People exploring GHK-Cu are usually focused on one of these:

Improve skin tone, firmness, and elasticity over time
Reduce the look of fine lines and wrinkles
Speed up post-procedure healing (after laser, microneedling, peels)
Support collagen production as they age
Encourage hair follicle health and reduce thinning
Help old wounds, scars, or stretch marks fade

What the science actually shows

GHK-Cu has the most published research of any peptide marketed for skin. Plain-English summary of what the evidence supports:

Collagen synthesis and skin firmness (topical)

Multiple human and lab studies show that topical GHK-Cu boosts collagen and elastin production in the skin and improves firmness measurements over weeks of use.1 2

Wound and burn healing (topical)

Clinical studies have used topical GHK-Cu on chronic wounds, post-surgical healing, and burns, with reports of faster epithelialization and better cosmetic outcomes.3

Anti-inflammatory and antioxidant effects

Lab work suggests GHK-Cu reduces inflammatory signals and has antioxidant activity, partly through its copper-cofactor role in superoxide dismutase. Helpful as a context for the skin findings, but not a clinical claim on its own.4

Hair follicle support

Smaller studies and lab models suggest GHK-Cu may extend the hair-growth phase and increase follicle size. Real-world results are modest and slow.5

Gene-expression effects (more speculative)

A frequently cited Pickart study reported that GHK-Cu shifted the expression of roughly 4,000 human genes in fibroblast cultures toward a younger pattern. The finding is striking but has not been replicated by independent groups at the same scale, and the clinical relevance to topical or injectable use is unclear.6

The honest read

What's solid:

Topical GHK-Cu has the most credible evidence of any peptide marketed for skin care, decades of cosmetic-chemistry research, multiple human studies on firmness and collagen, and a plausible mechanism via copper cofactor effects. For people interested in evidence-based skincare actives, it's a reasonable pick.

What's still unproven:

Injectable GHK-Cu has a much thinner evidence base than topical use. Effect sizes for skin tone and wrinkles in trials are real but modest, not the dramatic transformations marketing implies. The hair-follicle and wound-healing findings are promising but the clinical literature is still small. And the headline gene-expression findings deserve independent replication before being treated as established.

What's hyped beyond the evidence:

"Reverses aging" or "rebuilds skin" framings. Claims that injectable GHK-Cu produces dramatically better results than topical (no head-to-head studies). Claims that the gene-expression study proves anti-aging effects in humans. The cosmetic literature is meaningful; it's not a fountain of youth.

Things to know if you're looking into it

Topical vs injectable: the evidence base is much stronger for topical use. Topical serums and creams are widely available as cosmetics and don't require a prescription. Injectable research peptide is a separate product with much thinner clinical data.
Topical concentrations: commercial cosmetic formulations typically run from about 0.001% to 0.01% (10–100 mcg per mL). Higher isn't necessarily better, copper peptides are active at low concentrations and can cause irritation at high ones.
Skin reactions are possible: mild redness or irritation has been reported in roughly 10–20% of topical users in trials, especially when starting. Patch-testing on the inner forearm is the standard cautious approach.
Copper considerations: people with Wilson's disease or other copper-metabolism disorders should avoid copper peptides. People taking high-dose zinc supplements (which can interact with copper) should be aware of the interaction.
Regulatory status: not FDA-approved as a drug for any therapeutic indication. Cosmetic products containing GHK-Cu are regulated under the much lower bar that applies to cosmetics. Research-peptide injectable forms operate outside FDA drug oversight.
Healthcare provider involvement: recommended for anyone considering injectable use or using GHK-Cu post-procedure.
Specific dosing protocols, mechanism, and full reference list: all in the "Want to go deeper?" section below.

Reconstitution & dose calculator

Not FDA-approved as a drug. Calculator is for injectable use, not topical. The evidence base for GHK-Cu is much stronger for topical formulations than for injection — the dose math below applies only to the research-peptide injectable form. People with Wilson's disease or other copper-metabolism disorders should avoid copper peptides entirely. This is an educational reference, not dosing guidance.

BAC water works for most lots; switch to acetic acid + BAC mix if dissolution is cloudy or incomplete. GHK-Cu's copper coordination chemistry creates pH-dependent solubility issues in some lots. Standard reconstitution is straight bacteriostatic water (the defaults below assume that). If your reconstituted solution looks cloudy, has visible particles, or doesn't fully dissolve after gentle swirling and 5–10 minutes of sitting, start over with a small amount of 0.6% acetic acid water first, let it dissolve, then top up with BAC water to the target volume. The properly reconstituted solution should be clear with a faint blue tint from the copper.

Suggested start

1 mg/inj

Conservative entry into community protocols

Common range

1–3 mg/inj

2–3× weekly is the typical rhythm

Max dose

5 mg/inj

Upper bound of community protocols

Cycle

8–12 wks on

Then 4 weeks off — copper accumulation

Vial size

Bacteriostatic water

mL

Defaults to a 10 mg/mL dilution (5 mL into a 50 mg vial) — gives clean syringe units across the 1–5 mg dose range. If your vial can't hold 5 mL of headspace, drop to 2.5–3 mL (and the syringe units roughly double).

Dose per injection

mg

Subcutaneous injection. Most community protocols dose 2–3× weekly — the duration estimate below assumes 2× weekly.

Concentration

10.0 mg/mL

Per dose

0.10 mL

10 units on insulin syringe

Doses per vial

~50

~50 injections (~25.0 weeks) at 2× weekly

When to stay put vs. adjust

Stay put at 1 mg, 2–3× weekly, when results are gradually showing (skin tone, firmness, post-procedure recovery), when there's no injection-site irritation or unusual fatigue, and you're not approaching the cycle's end. GHK-Cu effects build slowly over weeks; resist the urge to escalate just because you don't see immediate change.

Consider stepping to 2–3 mg per injection only after at least four weeks at 1 mg with good tolerability and no clear progress. The 1–3 mg range is where most published protocols and community evidence sits. Above 3 mg per injection, you're in research-only territory.

Cycle off at the 8–12 week mark regardless of how well it's going. The 4-week off period isn't tradition for tradition's sake — copper is a metal that can accumulate, and giving the body a clearance window is the conservative move. Long-term continuous injectable use isn't well-studied.

The honest read on dosing. The strong GHK-Cu evidence base is for topical use. Injectable dose-finding studies in humans don't exist, so the numbers above come from community practice and small pilot work, not Phase 3 trials. The cosmetic use case has decades of data; the injectable use case is built on much thinner ground.

For educational and research purposes only. This is not medical advice. GHK-Cu is not FDA-approved as a drug. People with Wilson's disease or other copper-metabolism disorders should avoid copper peptides entirely. Consult a licensed healthcare provider before any health decision.

What people often ask

Does GHK-Cu actually work on wrinkles?

The topical evidence supports modest improvements in skin firmness, collagen content, and the appearance of fine lines over weeks of consistent use. "Modest" is the key word, meaningful, not dramatic.

Is topical or injectable better?

Topical has far more evidence. There are no head-to-head studies comparing them. Most of the dramatic before-and-after claims for injectable GHK-Cu come from anecdote, not trials.

Is GHK-Cu FDA-approved?

Not as a drug. Cosmetic products containing it are regulated under cosmetic rules, which set a much lower bar than drug approval. Injectable research peptide is not FDA-approved.

What about hair regrowth?

Some studies and lab work suggest GHK-Cu may extend the active growth phase of hair and increase follicle size. The real-world effect, where it exists, is gradual and modest. It's not a standalone hair-loss treatment.

What's the GLOW blend?

GLOW is a community-popular blend of BPC-157, TB-500, and GHK-Cu pitched for skin and tissue. There are no published human studies of that combination. Claims about its effectiveness are extrapolations from the individual peptides.

Are there side effects?

For topical use, mild irritation or redness is the most common report. For injectable use, the safety database is small. People with Wilson's disease or copper metabolism disorders should avoid it. People on high-dose zinc supplements should be aware of the interaction.

Why is the gene-expression study cited so often?

Pickart and colleagues reported that GHK-Cu shifted the expression of about 4,000 genes in fibroblast cultures toward a younger pattern. It's a striking finding, and a single in-vitro study from one research group. It deserves independent replication before being treated as the basis for clinical claims.

FDA and regulatory status

Status as of May 5, 2026: Not FDA-approved as a drug for any therapeutic indication. GHK-Cu is widely used as a cosmetic ingredient in skincare products under cosmetic-regulation rules (which set a much lower bar than drug approval). Injectable research-peptide forms are not FDA-approved and were not on the September 2023 FDA Category 2 list (which means compounding-pharmacy treatment is more permissive than for BPC-157 or TB-500, though commercial drug development has not been pursued). Status updates land here when they happen.

Want to go deeper? Mechanism, copper-coordination chemistry, studied dosing for topical and injectable use, side-effect profile, and full reference list. Click to expand.

Background and discovery

GHK-Cu (Glycyl-L-Histidyl-L-Lysine:Copper(II)) is a tripeptide composed of glycine, histidine, and lysine, complexed with a Cu²⁺ ion. Loren Pickart first isolated and characterized the GHK sequence in human plasma in 1973, while studying why plasma from younger donors produced different effects in liver-cell cultures than plasma from older donors. The copper-binding form (GHK-Cu) became the focus of subsequent research because it appeared more biologically active. It has been studied continuously in dermatology and wound-healing research for over five decades.

Mechanism of action

Copper coordination

The histidine residue plays a central role in coordinating the Cu²⁺ ion via its imidazole side chain. This particular coordination chemistry confers biological activity distinct from either GHK alone or free copper ions.

Collagen, elastin, and glycosaminoglycan synthesis

In dermal fibroblast cultures, GHK-Cu has been shown to upregulate type I collagen, elastin, decorin, and glycosaminoglycan production. These are the structural components most associated with skin firmness and elasticity.

Antioxidant and anti-inflammatory effects

Copper is a cofactor for superoxide dismutase. The GHK-Cu complex itself can scavenge reactive oxygen species. Multiple studies report reductions in inflammatory cytokine production in skin and wound models.

Gene expression (more speculative)

A 2010 microarray study from the Pickart group reported that GHK-Cu modulated the expression of approximately 4,000 human genes in fibroblast cultures, with patterns suggestive of "youthful" gene-expression profiles. The finding is intriguing and widely cited but has not been independently replicated at the same scale.

Commonly studied dosing protocols

These are not recommendations. Dosing varies widely by formulation, route, and indication. Always consult a licensed healthcare provider for any clinical decision.

Topical (cosmetic)

Commercial skincare products typically include GHK-Cu at 0.001% to 0.01% (10 to 100 mcg per mL). Application is once or twice daily to clean skin. Higher concentrations are not necessarily more effective and can increase the chance of irritation.

Subcutaneous (research range)

Reported research-community ranges are 1 to 2 mg per day, often delivered as 500 mcg to 1 mg twice daily. Human pharmacokinetics for injectable use have not been formally characterized.

Cycle considerations

Because copper accumulates with repeated dosing, longer cycles (8+ weeks) without breaks are sometimes flagged in research-community discussion as worth monitoring, especially in combination with other copper-containing supplements.

Side effects and safety profile

Topical use is generally well-tolerated. Reported side effects include mild redness or irritation in approximately 10–20% of users (particularly during initial application), with a smaller share reporting itching or burning. Injectable use has a much smaller safety database; reported side effects include mild injection-site reactions and, rarely, mild GI complaints.

Key contraindications:

Wilson's disease or other copper-metabolism disorders
Active copper sensitivity (uncommon)
Caution with high-dose zinc supplementation (zinc-copper interaction)

References

Pickart L. (2008). "The human tripeptide GHK and tissue remodeling." J Biomater Sci Polym Ed, 19(8), 969–988. PubMed
Maquart FX, Bellon G, Chaqour B, et al. (1993). "In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex GHK-Cu." J Clin Invest, 92(5), 2368–2376. PubMed
Mulder GD, Patt LM, Sanders L, et al. (1994). "Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper." Wound Repair Regen, 2(4), 259–269. PubMed
Pickart L, Vasquez-Soltero JM, Margolina A. (2012). "GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes." Cosmetics, 2(3), 236–247. MDPI
Pyo HK, Yoo HG, Won CH, et al. (2007). "The effect of tripeptide-copper complex on human hair growth in vitro." Arch Pharm Res, 30(7), 834–839. PubMed
Pickart L, Margolina A. (2010). "GHK-Cu and gene expression in human cells." Cosmetics & Toiletries, 125(2). PubMed
Pickart L, Margolina A. (2018). "Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data." Int J Mol Sci, 19(7), 1987. PubMed

For educational and research purposes only. This is not medical advice. GHK-Cu is not FDA-approved as a drug for any therapeutic indication; cosmetic products containing it are regulated under cosmetic rules. Consult a licensed healthcare provider before considering any peptide. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does. Information current as of May 2026.